Scholar Rock Holding Corporation
SRRK
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.6B
$55.33
▼ -1.09%
P/E
-16.72
Mkt Cap
$6.6B
52-Wk Range
$27.07–$61.76
52-Week Range
$27.07 - $61.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 75.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary latent myostatin inhibition technology with Phase 3 clinical validation
- First-mover advantage in growth factor signaling modulation for multiple indications
- Strategic partnership with Gilead Sciences providing resources and credibility
- Experienced management team with deep expertise in protein biology and drug development
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Apitegromab regulatory approval and commercialization potential in SMA market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+26.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SRRK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 6, 2026
Reported EPS of -$0.84 vs -$0.84 consensus (+0.1% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+0.1%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · Aug 21, 2026
vs Industry
How SRRK stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related